# A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

> **NCT06789445** · PHASE1,PHASE2 · RECRUITING · sponsor: **BlueRock Therapeutics** · enrollment: 54 (estimated)

## Conditions studied

- Primary Photoreceptor Disease
- Retinitis Pigmentosa (RP)
- Usher Syndrome
- Inherited Retinal Disease (IRD)
- Rod-Cone Dystrophy
- Rod-Cone Disease
- Retinal Degeneration
- Cone-Rod Disease (C-RD)
- Cone-Rod Dystrophy

## Interventions

- **BIOLOGICAL:** OpCT-001
- **BIOLOGICAL:** OpCT-001

## Key facts

- **NCT ID:** NCT06789445
- **Lead sponsor:** BlueRock Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2029-10
- **Final completion:** 2030-10
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06789445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06789445, "A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06789445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*